- Targeted protein degradation is an emerging therapeutic strategy that uses engineered molecules to selectively degrade disease-causing proteins, offering a novel approach to treat conditions that are difficult to address with traditional drugs. It is particularly impactful in oncology, neurodegenerative disorders, and autoimmune diseases
- The market’s growth is significantly driven by the rising need for more effective therapies for drug-resistant diseases and continued advancements in protein degradation technologies such as PROTACs and molecular glues. Increasing R&D investments by pharmaceutical and biotech companies further accelerate market expansion
- North America stands out as one of the dominant regions in the targeted protein degradation market, fueled by its strong biopharmaceutical sector, high research funding, and a growing number of clinical trials in this space
- For instance, the several leading U.S.-based biotech firms have entered strategic partnerships and licensing agreements to accelerate the development of targeted protein degraders, reinforcing the region’s leadership in this innovation-driven market
- Globally, targeted protein degradation platforms are considered one of the most promising frontiers in drug discovery and development, offering the potential to treat previously "undruggable" targets and fundamentally changing the landscape of precision medicine
